23andMe

23andMe Holding Co.
Company typePublic
NasdaqME
Industry
FoundedApril 2006 (2006-04)
Founders
Headquarters,
United States
Key people
Products
Services
RevenueIncrease US$299 million (2023)
Decrease US$−324 million (2023)
Decrease US$−312 million (2023)
Total assetsDecrease US$943 million (2023)
Total equityDecrease US$714 million (2023)
Number of employees
816 (2023)
Website23andme.com
Footnotes / references
Financials as of March 31, 2023[1]

23andMe Holding Co. is a publicly traded personal genomics and biotechnology company based in South San Francisco, California.[1][2] It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping,[3] to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.[4]

Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use.[5] Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.[6][7][8]

The company had a previously fraught relationship with the United States Food and Drug Administration (FDA) due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval.[9][10] 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014,[11][12][13] and in the UK since December 2014.[14]

23andMe became a publicly traded company in 2021 and soon had a market capitalization of US$6 billion.[15] By 2024, its valuation had fallen to 2% of that peak.[15]

  1. ^ a b "23andMe Holding Co. Fiscal 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. May 25, 2023.
  2. ^ Nguyen-Fleige, Chelsea (June 8, 2022). "23andMe has officially moved and downsized its HQ". American City Business Journals. Archived from the original on June 9, 2022.
  3. ^ Cite error: The named reference Wired2007 was invoked but never defined (see the help page).
  4. ^ "Fact Sheet". 23andMe. Archived from the original on January 19, 2013. Retrieved November 27, 2013.
  5. ^ "Autosomal SNP comparison chart - ISOGG Wiki". isogg.org. Retrieved September 4, 2022.
  6. ^ Cite error: The named reference Time was invoked but never defined (see the help page).
  7. ^ "About Us". 23andMe. Archived from the original on February 14, 2018. Retrieved February 11, 2018.
  8. ^ Janzen, Tim; et al. "Family Tree DNA Learning Center". Autosomal DNA testing comparison chart. Gene by Gene.
  9. ^ Herper, Matthew (December 5, 2013). "23andMe Stops Offering Genetic Tests Related to Health". Forbes. Archived from the original on February 9, 2014. Retrieved December 6, 2013.
  10. ^ Pollack, Andrew (October 21, 2015). "23andMe Will Resume Giving Users Health Data". The New York Times. ISSN 0362-4331. Archived from the original on March 4, 2016. Retrieved October 21, 2015.
  11. ^ Ubelacker, Sheryl (October 1, 2014). "U.S. company launches genetic health and ancestry info service in Canada". Winnipeg Free Press. The Canadian Press. Retrieved October 7, 2014.
  12. ^ Hansen, Darah (October 2, 2014). "5Q: Anne Wojcicki, CEO 23andMe on knowing your DNA data (and being married to the boss of Google)". Yahoo Finance Canada. Retrieved October 7, 2014.
  13. ^ "23andme genetic testing service raises ethical questions". CBC News. October 2, 2014. Retrieved October 7, 2014.
  14. ^ Roberts, Michelle; Rincon, Paul (December 2, 2014). "Controversial DNA test comes to UK". BBC News. Retrieved December 2, 2014.
  15. ^ a b Winkler, Rolfe (January 31, 2024). "23andMe's Fall From $6 Billion to Nearly $0". Wall Street Journal.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search